4164-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-3926]

Request for Nominations for Voting Members on Public Advisory Panels of the Medical Devices Advisory Committee

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for voting members to serve on the Medical Devices Advisory Committee (MDAC) device panels in the Center for Devices and Radiological Health. This annual notice is also in accordance with the 21st Century Cures Act, which requires the Secretary of Health and Human Services (the Secretary) to provide an annual opportunity for patients, representatives of patients, and sponsors of medical devices that may be specifically the subject of a review by a classification panel to provide recommendations for individuals with appropriate expertise to fill voting member positions on classification panels. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees, and therefore, encourages nominations of appropriately qualified candidates from these groups.

**DATES:** Nominations received on or before [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE *FEDERAL REGISTER*], will be given first consideration for membership on the Panels of the MDAC. Nominations received after [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE *FEDERAL REGISTER*], will be considered for nomination to the committee as later vacancies occur.

**ADDRESSES:** All nominations for membership should be submitted electronically by logging into the FDA Advisory Nomination Portal at

https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm or by mail to Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993-0002. Information about becoming a member on an FDA advisory committee can also be obtained by visiting FDA's website at https://www.fda.gov/AdvisoryCommittees/default.htm.

**FOR FURTHER INFORMATION CONTACT:** Regarding all nomination questions for membership, contact the following persons listed in table 1:

Table 1.--Primary Contact and Committee or Panel

Primary Contact Person	Committee or Panel
Joannie Adams-White, Office of the Center Director, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5561, Silver Spring, MD 20993, 301-796-5421, Joannie.Adams-White@fda.hhs.gov	Medical Devices Dispute Resolution Panel
James P. Swink, Office of Management, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66 Rm. 5211, Silver Spring, MD 20993, 301-796-6313, James.Swink@fda.hhs.gov	Circulatory System Devices Panel, Immunology Devices Panel, Microbiology Devices Panel, Ophthalmic Devices Panel.
Akinola Awojope, Office of Management, Center for Devices and Radiological Health, Food and Drug Administration,10903 New Hampshire Ave., Bldg. 66, Rm. 5216, Silver Spring, MD 20993, 301-636-0512, Akinola.Awojope@fda.hhs.gov	Dental Products Panel, Neurological Devices Panel, Obstetrics and Gynecology Devices Panel Orthopaedic and Rehabilitation Devices Panel.
Jarrod Collier, Office of Management, Center for Devices and Radiological Health, Food and Drug Administration,10903 New Hampshire Ave., Bldg. 66, Rm. 5216, Silver Spring, MD 20993, 301-796- 6875, Jarrod.Collier@fda.hhs.gov	Ear, Nose and Throat Devices Panel, General Hospital and Personal Use Devices Panel, Hematology and Pathology Devices Panel, Molecular and Clinical Genetics Panel, Radiological Devices Panel.
Candace Nalls, Office of Management, Center for Devices and Radiological Health, Food and Drug Administration,10903 New Hampshire Ave., Bldg. 66, Rm. 5214, Silver Spring, MD 20993, 301-636- 0510, Candace.Nalls@fda.hhs.gov	Anesthesiology and Respiratory Therapy Devices Panel, Clinical Chemistry and Clinical Toxicology Devices Panel, General and Plastic Surgery Devices Panel.

## **SUPPLEMENTARY INFORMATION:** FDA is requesting nominations for voting members

for vacancies listed in table 2:

Table 2.--Expertise Needed, Vacancies, and Approximate Date Needed

Expertise Needed	Vacancies	Approximate Date Needed

Anesthesiology and Respiratory Therapy Devices	3	Immediately
Panel of the Medical Devices Advisory Committee-		•
-Anesthesiologists, pulmonary medicine		
specialists, or other experts who have specialized		
interests in ventilator support, sleep medicine,		
pharmacology, physiology, or the effects and		
complications of anesthesia. FDA is also seeking		
applicants with pediatric expertise in these areas.		
Circulatory System Devices Panel of the Medical	1	Immediately
Devices Advisory CommitteeInterventional	1	July 1, 2022
cardiologists, electrophysiologists, invasive	1	541y 1, 2022
(vascular) radiologists, vascular and cardiothoracic		
surgeons, and cardiologists with special interest in		
congestive heart failure.		
Clinical Chemistry and Clinical Toxicology Panel	1	March 1, 2022
,	1	Waten 1, 2022
of the Medical Devices Advisory Committee		
Doctors of medicine or philosophy with experience		
in clinical chemistry (e.g., cardiac markers),		
clinical toxicology, clinical pathology, clinical		
laboratory medicine, and endocrinology.	_	<u> </u>
Dental Products Panel of the Medical Devices	3	Immediately
Advisory CommitteeDentists, engineers, and		
scientists who have expertise in the areas of dental		
implants, dental materials, oral and maxillofacial		
surgery, endodontics, periodontology, tissue		
engineering, snoring/sleep therapy, and dental		
anatomy.		
Ear, Nose, and Throat Devices Panel of the	4	Immediately
Medical Devices Advisory CommitteeOtologists,		-
neurotologists, and audiologists.		
General and Plastic Surgery Devices Panel of the	4	Immediately
Medical Devices Advisory CommitteeSurgeons		,
(general, plastic, reconstructive, pediatric, thoracic,		
abdominal, pelvic, and endoscopic);		
dermatologists; experts in biomaterials, lasers,		
wound healing, and quality of life; and		
biostatisticians.		
General Hospital and Personal Use Devices Panel	2	Immediately
of the Medical Devices Advisory Committee	1	January 1, 2022
Internists, pediatricians, neonatologists,	1	January 1, 2022
endocrinologists, gerontologists, nurses,		
biomedical engineers, human factors experts, or		
microbiologists/infection control practitioners or		
experts.	2	I 1: 4-1
Hematology and Pathology Devices Panel of the	3	Immediately
Medical Devices Advisory Committee	1	March 1, 2022
Hematologists (benign and/or malignant		
hematology), hematopathologists (general and		
special hematology, coagulation and hemostasis,		
and hematological oncology), gynecologists with		
special interests in gynecological oncology,		
cytopathologists, and molecular pathologists with		
special interests in development of predictive and		
prognostic biomarkers, molecular oncology, cancer		
screening, cancer risk, digital pathology, whole		
slide imaging; devices utilizing artificial		
intelligence/machine learning.		
Immunology Devices Panel of the Medical Devices	7	Immediately
Advisory CommitteePersons with experience in		
medical, surgical, or clinical oncology, internal		
medicine, clinical immunology, allergy, molecular		
diagnostics, or clinical laboratory medicine.		
angliostics, of chilical incolutory medicine.		

Medical Devices Dispute Resolution Panel of the Medical Devices Advisory CommitteeExperts with cross-cutting scientific, clinical, analytical or mediation skills.  Microbiology Devices Panel of the Medical 5 Immediately Devices Advisory CommitteeInfectious disease clinicians (e.g., pulmonary disease specialists, sexually transmitted disease specialists, pediatric ID specialists, tropical diseases specialists) and clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the 2 Immediately Medical Devices Advisory CommitteeExperts in 2 June 1, 2022 human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn errors of metabolism, biochemical and/or
with cross-cutting scientific, clinical, analytical or mediation skills.  Microbiology Devices Panel of the Medical Devices Advisory CommitteeInfectious disease clinicians (e.g., pulmonary disease specialists, sexually transmitted disease specialists, pediatric ID specialists, tropical diseases specialists) and clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
mediation skills.  Microbiology Devices Panel of the Medical Devices Advisory CommitteeInfectious disease clinicians (e.g., pulmonary disease specialists, sexually transmitted disease specialists, pediatric ID specialists, tropical diseases specialists) and clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
Microbiology Devices Panel of the Medical Devices Advisory CommitteeInfectious disease clinicians (e.g., pulmonary disease specialists, sexually transmitted disease specialists, pediatric ID specialists, tropical diseases specialists) and clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
Devices Advisory CommitteeInfectious disease clinicians (e.g., pulmonary disease specialists, sexually transmitted disease specialists, pediatric ID specialists, tropical diseases specialists) and clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
clinicians (e.g., pulmonary disease specialists, sexually transmitted disease specialists, pediatric ID specialists, tropical diseases specialists) and clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
clinicians (e.g., pulmonary disease specialists, sexually transmitted disease specialists, pediatric ID specialists, tropical diseases specialists) and clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
sexually transmitted disease specialists, pediatric ID specialists, tropical diseases specialists) and clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
ID specialists, tropical diseases specialists) and clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
clinical microbiologists experienced in emerging infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
infectious diseases; clinical microbiology laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
laboratory directors; molecular biologists with experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
experience in in vitro diagnostic device testing; virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
virologists; hepatologists; or clinical oncologists experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
experienced with tumor resistance and susceptibility.  Molecular and Clinical Genetics Panel of the Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
susceptibility.  Molecular and Clinical Genetics Panel of the  Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
Molecular and Clinical Genetics Panel of the  Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
Medical Devices Advisory CommitteeExperts in human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
human genetics, molecular diagnostics, and in the clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
clinical management of patients with genetic disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
disorders, and (e.g., pediatricians, obstetricians, neonatologists). Individuals with training in inborn
neonatologists). Individuals with training in inborn
errors of metabolism, blochemical and/or
molecular genetics, population genetics,
epidemiology and related statistical training,
bioinformatics, computational genetics/genomics,
variant classification, cancer genetics/genomics,
molecular oncology, radiation biology, and clinical
molecular genetics testing, (e.g., sequencing,
whole exome sequencing, whole genome
sequencing, non-invasive prenatal testing, cancer
screening, circulating cell free/circulating tumor
nucleic acid testing, digital PCR, genotyping, array
CGH, etc.). Individuals with experience in
genetics counseling, medical ethics are also
desired, and individuals with experience in
ancillary fields of study will be considered.
Neurological Devices Panel of the Medical 2 Immediately
Devices Advisory CommitteeNeurosurgeons
(cerebrovascular and pediatric), neurologists
(stroke, pediatric, pain management, and
movement disorders), interventional
neuroradiologists, psychiatrists, and
biostatisticians.
Obstetrics and Gynecology Devices Panel of the 4 Immediately
Medical Devices Advisory CommitteeExperts in 1 February 1, 2022
perinatology, embryology, reproductive
endocrinology, pediatric gynecology,
gynecological oncology, operative hysteroscopy,
pelviscopy, electrosurgery, laser surgery, assisted
reproductive technologies, contraception,
postoperative adhesions, and cervical cancer and
colposcopy; biostatisticians and engineers with
experience in obstetrics/gynecology devices;
urogynecologists; experts in breast care; experts in
gynecology in the older patient; experts in
diagnostic (optical) spectroscopy; experts in
midwifery; labor and delivery nursing.
Ophthalmic Devices Panel of the Medical Devices 4 Immediately
Advisory CommitteeOphthalmologists
specializing in cataract and refractive surgery and
vitreo-retinal surgery, in addition to vision

		,
scientists, optometrists, and biostatisticians		
practiced in ophthalmic clinical trials.		
Orthopaedic and Rehabilitation Devices Panel of	2	Immediately
the Medical Devices Advisory Committee	2	September 1, 2022
Orthopaedic surgeons (joint, spine, trauma,		
reconstruction, sports medicine, hand, foot and		
ankle, and pediatric orthopaedic surgeons);		
rheumatologists; engineers (biomedical,		
biomaterials, and biomechanical); experts in		
rehabilitation medicine, and musculoskeletal		
engineering; radiologists specializing		
musculoskeletal imaging and analyses and		
biostatisticians.		
Radiological Devices Panel of the Medical Devices	3	Immediately
Advisory CommitteePhysicians with experience	4	February 1, 2022
in general radiology, mammography, ultrasound,		
magnetic resonance, computed tomography, other		
radiological subspecialties and radiation oncology;		
scientists with experience in diagnostic devices,		
radiation physics, statistical analysis, digital		
imaging and image analysis.		

## I. General Description of the Committee Duties

The MDAC reviews and evaluates data on the safety and effectiveness of marketed and investigational devices and makes recommendations for their regulation. The panels engage in many activities to fulfill the functions the Federal Food, Drug, and Cosmetic Act (FD&C Act) envisions for device advisory panels. With the exception of the Medical Devices Dispute Resolution Panel, each panel, according to its specialty area, performs the following duties: (1) advises the Commissioner regarding recommended classification or reclassification of devices into one of three regulatory categories, (2) advises on any possible risks to health associated with the use of devices, (3) advises on formulation of product development protocols, (4) reviews premarket approval applications for medical devices, (5) reviews guidelines and guidance documents, (6) recommends exemption of certain devices from the application of portions of the FD&C Act, (7) advises on the necessity to ban a device, and (8) responds to requests from the Agency to review and make recommendations on specific issues or problems concerning the safety and effectiveness of devices. With the exception of the Medical Devices Dispute Resolution Panel, each panel, according to its specialty area, may also make appropriate recommendations to the Commissioner on issues relating to the design of clinical studies

regarding the safety and effectiveness of marketed and investigational devices.

The Dental Products Panel also functions at times as a dental drug panel. The functions of the dental drug panel are to evaluate and recommend whether various prescription drug products should be changed to over-the-counter status and to evaluate data and make recommendations concerning the approval of new dental drug products for human use.

The Medical Devices Dispute Resolution Panel provides advice to the Commissioner on complex or contested scientific issues between FDA and medical device sponsors, applicants, or manufacturers relating to specific products, marketing applications, regulatory decisions and actions by FDA, and Agency guidance and policies. The panel makes recommendations on issues that are lacking resolution, are highly complex in nature, or result from challenges to regular advisory panel proceedings or Agency decisions or actions.

## II. Criteria for Voting Members

The MDAC with its 18 panels shall consist of a maximum of 159 standing members. Members are selected by the Commissioner or designee from among authorities in clinical and administrative medicine, engineering, biological and physical sciences, and other related professions. Almost all non-Federal members of this committee serve as Special Government Employees. A maximum of 122 members shall be standing voting members and 37 shall be nonvoting members who serve as representatives of consumer interests and of industry interests. FDA is publishing separate documents announcing the Request for Nominations Notification for Nonvoting Representatives on certain panels of the MDAC. Persons nominated for membership on the panels should have adequately diversified experience appropriate to the work of the panel in such fields as clinical and administrative medicine, engineering, biological and physical sciences, statistics, and other related professions. The nature of specialized training and experience necessary to qualify the nominee as an expert suitable for appointment may include experience in medical practice, teaching, and/or research relevant to the field of activity of the panel. The current needs for each panel are listed in table 2. Members will be invited to serve

for terms of up to 4 years.

III. Nomination Procedures

Any interested person may nominate one or more qualified individuals for membership

on one or more of the advisory panels. Self-nominations are also accepted. Nominations must

include a current, complete résumé or curriculum vitae for each nominee, including current

business address, telephone number, and email address if available and a signed copy of the

Acknowledgement and Consent form available at the FDA Advisory Nomination Portal (see

ADDRESSES). Nominations must also specify the advisory panel(s) for which the nominee is

recommended. Nominations must also acknowledge that the nominee is aware of the nomination

unless self-nominated. FDA will ask potential candidates to provide detailed information

concerning such matters related to financial holdings, employment, and research grants and/or

contracts to permit evaluation of possible sources of conflict of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21

CFR part 14, relating to advisory committees.

Dated: December 13, 2021.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2021-27376 Filed: 12/16/2021 8:45 am; Publication Date: 12/17/2021]